| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/18/2009 | EP2035416A1 Substituted piperidines that increase p53 activity and the uses thereof |
| 03/18/2009 | EP2035413A2 Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors |
| 03/18/2009 | EP2035412A1 Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia |
| 03/18/2009 | EP2035411A1 Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia. |
| 03/18/2009 | EP2035409A1 Benzimidazole derivatives which are to be used as anatgonist for the cb1-receptor |
| 03/18/2009 | EP2035408A1 Sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| 03/18/2009 | EP2035407A1 Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia |
| 03/18/2009 | EP2035406A1 Novel substituted-1h-quinazoline-2,4-dione derivatives, preparation method thereof and pharmaceutical composition containing the same |
| 03/18/2009 | EP2035404A1 Crystalline duloxetine hydrochloride |
| 03/18/2009 | EP2035403A1 Crystalline duloxetine hydrochloride |
| 03/18/2009 | EP2035397A1 Chemical compounds |
| 03/18/2009 | EP2035396A2 Triazole compounds that modulate hsp90 activity |
| 03/18/2009 | EP2035394A1 2-pyrazinecarboxamide derivatives |
| 03/18/2009 | EP2035392A1 Imidazole kv1. 5 potassium channel inhibitors |
| 03/18/2009 | EP2035391A1 Indazole derivatives for treating hsp90-induced diseases |
| 03/18/2009 | EP2035389A1 Therapeutic agents |
| 03/18/2009 | EP2035388A1 Therapeutic agents |
| 03/18/2009 | EP2035387A2 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same |
| 03/18/2009 | EP2035386A1 Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases |
| 03/18/2009 | EP2035385A2 Inhibitors of akt (protein kinase b) |
| 03/18/2009 | EP2035380A2 Parp inhibitors |
| 03/18/2009 | EP2035379A2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 03/18/2009 | EP2035378A1 Substituted isoindoles as bace inhibitors and their use |
| 03/18/2009 | EP2035377A1 Indole derivatives and their use as thyroid receptor ligands |
| 03/18/2009 | EP2035376A1 Indoline amide derivatives as ep4 receptor ligands |
| 03/18/2009 | EP2035373A1 Phenyl pyrrole aminoguanidine derivatives |
| 03/18/2009 | EP2035372A1 Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| 03/18/2009 | EP2035370A2 Tetralin and indane derivatives and uses thereof |
| 03/18/2009 | EP2035369A1 Therapeutic compounds |
| 03/18/2009 | EP2035367A1 Ship 1 modulator prodrugs |
| 03/18/2009 | EP2035360A1 Ship 1 modulator compounds |
| 03/18/2009 | EP2035092A2 Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload |
| 03/18/2009 | EP2035040A2 Pharmaceutical composition for administration by injection |
| 03/18/2009 | EP2035038A2 Compositions and methods for treating polycystic kidney disease |
| 03/18/2009 | EP2035029A2 Peptide compounds for treating refractory status epilepticus |
| 03/18/2009 | EP2035017A2 Polymers with antimicrobial activity containing quaternary ammonium groups |
| 03/18/2009 | EP2035016A2 Indenoisoquinoline-releasable polymer conjugates |
| 03/18/2009 | EP2035015A2 Compositions, methods, and kits for treating dry eye |
| 03/18/2009 | EP2035014A2 Fucoidan compositions and methods |
| 03/18/2009 | EP2035013A1 Use of defibrotide for the inhibition of heparanase |
| 03/18/2009 | EP2035012A2 Mannitol and/or proline for prevention and treatment of ageing related symptoms |
| 03/18/2009 | EP2035011A2 C-glycolipids with enhanced th-1 profile |
| 03/18/2009 | EP2035010A1 Modulation of the immune system by inositol phospholipids |
| 03/18/2009 | EP2035009A1 Prolonged improvement of renal function comprising infrequent administration of an aa1ra |
| 03/18/2009 | EP2035008A2 Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals |
| 03/18/2009 | EP2035007A1 Use of adenosine a1 antagonist in radiocontrast media induced nephropathy |
| 03/18/2009 | EP2035006A1 Use of allopurinol for the treatment of palmar plantar erythrodysesthesia |
| 03/18/2009 | EP2035005A2 Therapy using cytokine inhibitors |
| 03/18/2009 | EP2035004A1 Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity |
| 03/18/2009 | EP2035003A1 A method of reducing amyloid-beta peptide levels using a bisdioxopiperazine |
| 03/18/2009 | EP2035000A1 Hif hydroxylase inhibitors for treatment of anemia of cancer |
| 03/18/2009 | EP2034999A2 Dha esters and use thereof in treatment and prevention of cardiovascular disease |
| 03/18/2009 | EP2034998A1 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors |
| 03/18/2009 | EP2034997A1 Antibacterial compositions |
| 03/18/2009 | EP2034996A2 Triazole compounds that modulate hsp90 activity |
| 03/18/2009 | EP2034995A2 Method for treating proliferative disorders associated with protooncogene products |
| 03/18/2009 | EP2034994A2 Nf-kappa b inhibitors and uses thereof |
| 03/18/2009 | EP2034993A2 Pyrazinones as cellular proliferation inhibitors |
| 03/18/2009 | EP2034992A2 Method of improved diuresis in individuals with impaired renal function |
| 03/18/2009 | EP2034991A1 Preparation for preventing ageing symptoms containing phytoestrogens and melatonin |
| 03/18/2009 | EP2034990A2 Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
| 03/18/2009 | EP2034989A2 Methods and compositions for improving cognitive function |
| 03/18/2009 | EP2034988A2 Compositions and kits comprising a melatonin component and a flavanol component |
| 03/18/2009 | EP2034987A1 New use for cannabinoid |
| 03/18/2009 | EP2034986A2 High dose oral pharmaceutical compositions of artemether and lumefantrine |
| 03/18/2009 | EP2034985A1 Combination of an hmg-coa reductase inhibitor and a farnesyl-pyrophosphatase synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins |
| 03/18/2009 | EP2034984A2 Method of treating atrophic vaginitis |
| 03/18/2009 | EP2034983A1 Use of a polyunsaturated fatty acid compound |
| 03/18/2009 | EP2034982A1 Composition for foodstuff for binding acetaldehyde |
| 03/18/2009 | EP2034981A1 Diamidine inhibitors of tdp1 |
| 03/18/2009 | EP2034979A2 Treatment of cnidaria intoxication with vanilloid receptor antagonists |
| 03/18/2009 | EP2034977A2 Use of opioid receptor antagonists |
| 03/18/2009 | EP2034974A2 Lipoic acid pellets |
| 03/18/2009 | EP2034971A2 Steroid-containing sustained release intraocular implants and related methods |
| 03/18/2009 | EP2034970A2 Sustained release pharmaceutical formulation comprising phenylephrine |
| 03/18/2009 | EP2034969A2 Immediate-release tablet formulations of a thrombin receptor antagonist |
| 03/18/2009 | EP2034968A1 Galenical formulations of aliskiren and hydrochlorothiazide |
| 03/18/2009 | EP2034967A1 Oral pharmaceutical composition of a poorly water-soluble active substance |
| 03/18/2009 | EP2034966A1 A stabilised composition comprising ace inhibitors |
| 03/18/2009 | EP2034964A2 Process for producing nanoparticles by spray drying |
| 03/18/2009 | EP2034959A2 Optimized fluorocarbon emulsions for blood substitutes and other therapeutic uses |
| 03/18/2009 | EP2034958A2 Stable aqueous suspension having palatable taste |
| 03/18/2009 | EP2034957A2 Pharmaceutical composition for oral administration |
| 03/18/2009 | EP2034952A2 Aprepitant compositions |
| 03/18/2009 | EP2034854A1 Nutritional formulation |
| 03/18/2009 | EP2034844A2 Method for treatment of diarrhea-predominant irritable bowel syndrome |
| 03/18/2009 | EP2034839A2 Treatment of neurodegenerative diseases through inhibiton of hsp90 |
| 03/18/2009 | EP2034838A2 Novel compounds |
| 03/18/2009 | EP2034835A2 Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone |
| 03/18/2009 | EP2034834A2 PRODRUGS OF 5-AMINO-3-(3'-DEOXY-BETA -D-RIBOFURANOSYL)-THIAZOLO[4,5-d]PYRIMIDIN-2,7-DIONE |
| 03/18/2009 | EP2034832A2 Il-8 receptor antagonist |
| 03/18/2009 | EP2034829A1 Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association |
| 03/18/2009 | EP2034828A2 Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers |
| 03/18/2009 | EP2034826A2 Method of inhibiting the transmission of influenza virus |
| 03/18/2009 | EP2000467A9 Hydrate for medical purposes |
| 03/18/2009 | EP2000137A9 Triglyceride-lowering agent and hyperinsulinism-ameliorating agent |
| 03/18/2009 | EP1994042A4 Preparation of gemcitabine |
| 03/18/2009 | EP1948131B1 Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator |
| 03/18/2009 | EP1940376B1 Use of neboglamine in the treatment of toxicodependency |
| 03/18/2009 | EP1928407B1 Chronotherapeutic ocular delivery system comprising a combination of prostaglandin and a beta-blocker for treating primary glaucoma |